StockData
Gossamer Bio, Inc. logo

Gossamer Bio, Inc. (GOSS) stock

GOSSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 1/30
$11.04+0.06 (+0.55%)

Close on Nov 17, 2026Market cap $5.40BP/E –Yield –

Gossamer Bio r&d expenses

Research and development expenses are spending on new products and technology.

Gossamer Bio's R&D Expenses for the twelve months ending Jun 30, 2026 was $163.96M, up 8.9% year over year. For fiscal 2025 it was $174.09M, up 25.7% from the year before. The highest annual figure on record is $174.09M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$174.09M+25.7%
FY2024Dec 31, 2024$138.49M+2.4%
FY2023Dec 31, 2023$135.30M-20.8%
FY2022Dec 31, 2022$170.92M+0.4%
FY2021Dec 31, 2021$170.27M+5.9%
FY2020Dec 31, 2020$160.85M+12.2%
FY2019Dec 31, 2019$143.40M+159.4%
FY2018Dec 31, 2018$55.28M+6104.6%
FY2017Dec 31, 2017$891.00K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$26.41M-36.5%
Q1 FY2026Mar 31, 2026$43.08M+13.2%
Q4 FY2025Dec 31, 2025$48.94M+35.5%
Q3 FY2025Sep 30, 2025$45.54M+30.5%
Q2 FY2025Jun 30, 2025$41.58M+18.5%
Q1 FY2025Mar 31, 2025$38.04M+17.4%
Q4 FY2024Dec 31, 2024$36.11M+20.5%
Q3 FY2024Sep 30, 2024$34.90M+11.8%
Q2 FY2024Jun 30, 2024$35.09M-3.4%
Q1 FY2024Mar 31, 2024$32.39M-14.3%
Q4 FY2023Dec 31, 2023$29.97M-27.8%
Q3 FY2023Sep 30, 2023$31.20M-29.9%
Q2 FY2023Jun 30, 2023$36.31M-14.7%
Q1 FY2023Mar 31, 2023$37.80M-10.7%
Q4 FY2022Dec 31, 2022$41.51M+1.4%
Q3 FY2022Sep 30, 2022$44.51M+3.1%
Q2 FY2022Jun 30, 2022$42.58M-3.9%
Q1 FY2022Mar 31, 2022$42.32M+1.2%
Q4 FY2021Dec 31, 2021$40.93M+5.2%
Q3 FY2021Sep 30, 2021$43.19M+3.2%
Q2 FY2021Jun 30, 2021$44.32M+14.6%
Q1 FY2021Mar 31, 2021$41.83M+1.0%
Q4 FY2020Dec 31, 2020$38.91M-8.7%
Q3 FY2020Sep 30, 2020$41.85M+4.2%
Q2 FY2020Jun 30, 2020$38.68M+8.4%
Q1 FY2020Mar 31, 2020$41.41M+65.8%
Q4 FY2019Dec 31, 2019$42.60M+64.6%
Q3 FY2019Sep 30, 2019$40.15M+112.9%
Q2 FY2019Jun 30, 2019$35.68M+349.9%
Q1 FY2019Mar 31, 2019$24.98M+852.1%
Q4 FY2018Dec 31, 2018$25.87M–
Q3 FY2018Sep 30, 2018$18.86M–
Q2 FY2018Jun 30, 2018$7.93M–
Q1 FY2018Mar 31, 2018$2.62M–

More Gossamer Bio figures

See a number that looks wrong?